Publication | Closed Access

Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer

Dual Pi3k/mtor InhibitorPhase 1/1BBreast OncologyOncologyMedicineBreast CancerAnti-cancer AgentCancer TreatmentExpansion StudyPharmacologyRadiation OncologyRadiologyHealth Sciences